Name of organisation
1) Department/Research groupDAPI
2) Organisation/affiliationDeutsches Arzneiprüfungsinstitut e.V. (DAPI)
Short Name in the inventoryDAPI
Administrative Contact
Title Ms
Last name Werning
First name Johanna
Address line 1Unter den Linden 19-23
Address line 2
Address line 3
CityBerlin
Postcode10117
CountryGermany
Phone number (incl. country code)49-30-40004572
Alternative phone number
Fax number (incl. country code)49-30-40004573
Scientific Contact
Title Ms
Last name Werning
First name Johanna
Address line 1Unter den Linden 19-23
Address line 2
Address line 3
CityBerlin
Postcode10117
CountryGermany
Phone number (incl. country code)49-30-40004572
Alternative phone number
Fax number (incl. country code)49-30-40004573
Alternative Scientific Contact
Title Ms
Last name Kieble
First name Marita
Address line 1Unter den Linden 19-23
Address line 2
Address line 3
CityBerlin
Postcode10117
CountryGermany
Phone number (incl. country code)49-30-40004572
Alternative phone number
Fax number (incl. country code)49-30-40004573
2. Description
The German Institute for Drug Use Evaluation (Deutsches Arzneiprüfungsinstitut e. V. (DAPI)) is a non-profit association active in the area of pharmacoepidemiology and pharmacoeconomics.
The DAPI operates a database comprising anonymous claims data of prescribed medicinal products dispensed at community pharmacies in the Federal Republic of Germany at the expense of the statutory health insurance (GKV) funds. Roughly 90 % of Germany's population is insured by this system (approx. 70 million people).
Over recent years, the DAPI has acquired expertise in the planning and conduct of pharmacoepidemiologic studies with a special focus on compliance/persistence research.
3. Category
Charity or non-profit organisation
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Infectious diseases
Liver disease
Psychiatry
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Drug Utilisation
7. Experience in collecting data directly from individual patients/respondents
None
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
No
Interactive voice response systems
No
Call centre
No